金黄色葡萄球菌拓扑异构酶IV的GrlA突变对喹诺酮和香豆素活性的影响。
Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity.
作者信息
Fournier B, Hooper D C
机构信息
Infectious Disease Division and Medical Services, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114-2696, USA.
出版信息
Antimicrob Agents Chemother. 1998 Aug;42(8):2109-12. doi: 10.1128/AAC.42.8.2109.
Abstract
The grlA genes of Staphylococcus aureus ISP794 (wild type), MT5224c4 (grlA [Phe-80]), MT5224c2 (grlA [Pro-116]), and MT111 (grlA [Glu-116]) were cloned in pSK950, a shuttle vector, and introduced into S. aureus strains derived from strain RN4220. The mutations at position 116 of GrlA (Ala-->Pro or Glu) caused an increase in the level of fluoroquinolone resistance and a decrease in the level of coumarin susceptibility, whereas the mutation at position 80 (Ser-->Phe) caused only an increase in the level of fluoroquinolone resistance. In multicopy alleles, both types of mutations were codominant for fluoroquinolone resistance, and mutations at position 116 were also codominant for coumarin resistance.
摘要
金黄色葡萄球菌ISP794（野生型）、MT5224c4（grlA [Phe-80]）、MT5224c2（grlA [Pro-116]）和MT111（grlA [Glu-116]）的grlA基因被克隆到穿梭载体pSK950中，并导入源自RN4220菌株的金黄色葡萄球菌菌株。GrlA第116位的突变（Ala→Pro或Glu）导致氟喹诺酮耐药水平增加，香豆素敏感性水平降低，而第80位的突变（Ser→Phe）仅导致氟喹诺酮耐药水平增加。在多拷贝等位基因中，两种类型的突变对氟喹诺酮耐药均为共显性，第116位的突变对香豆素耐药也为共显性。
相似文献
1
Effects of mutations in GrlA of topoisomerase IV from Staphylococcus aureus on quinolone and coumarin activity.金黄色葡萄球菌拓扑异构酶IV的GrlA突变对喹诺酮和香豆素活性的影响。
Antimicrob Agents Chemother. 1998 Aug;42(8):2109-12. doi: 10.1128/AAC.42.8.2109.
2
Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.金黄色葡萄球菌拓扑异构酶IV和DNA促旋酶的突变：对喹诺酮和香豆素活性的新型多效性影响。
Antimicrob Agents Chemother. 1998 Jan;42(1):121-8. doi: 10.1128/AAC.42.1.121.
3
Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.曲伐沙星与其他氟喹诺酮类药物对金黄色葡萄球菌纯化的拓扑异构酶以及gyrA和grlA突变体的活性比较。
Antimicrob Agents Chemother. 1999 Aug;43(8):1845-55. doi: 10.1128/AAC.43.8.1845.
4
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.拓扑异构酶IV中的喹诺酮耐药性突变：与flqA位点的关系以及金黄色葡萄球菌中拓扑异构酶IV是氟喹诺酮类药物的主要靶点而DNA回旋酶是次要靶点的遗传学证据。
Antimicrob Agents Chemother. 1996 Aug;40(8):1881-8. doi: 10.1128/AAC.40.8.1881.
5
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.金黄色葡萄球菌DNA拓扑异构酶IV的克隆及一级结构：氟喹诺酮类药物的主要作用靶点
Mol Microbiol. 1994 Aug;13(4):641-53. doi: 10.1111/j.1365-2958.1994.tb00458.x.
6
Mechanism of quinolone resistance in Staphylococcus aureus.金黄色葡萄球菌对喹诺酮类药物耐药的机制。
J Infect Chemother. 2000 Sep;6(3):131-9. doi: 10.1007/s101560070010.
7
Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.耐曲伐沙星金黄色葡萄球菌中的拓扑异构酶突变
Antimicrob Agents Chemother. 1998 Aug;42(8):2122-4. doi: 10.1128/AAC.42.8.2122.
8
Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.负责金黄色葡萄球菌喹诺酮耐药性的DNA拓扑异构酶IV grlA基因的改变。
Antimicrob Agents Chemother. 1996 May;40(5):1157-63. doi: 10.1128/AAC.40.5.1157.
9
Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.金黄色葡萄球菌对普马沙星的耐药机制及频率：新突变提示新的药物-靶点相互作用
Antimicrob Agents Chemother. 2000 Dec;44(12):3344-50. doi: 10.1128/AAC.44.12.3344-3350.2000.
10
Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.喹诺酮耐药性的分子流行病学及新型喹诺酮类药物对欧洲金黄色葡萄球菌分离株的体外活性比较
FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):281-7. doi: 10.1111/j.1574-695X.1999.tb01400.x.
引用本文的文献
1
DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases.DX-619，一种新型去氟（6）喹诺酮，对耐甲氧西林金黄色葡萄球菌突变体的选择频率较低：喹诺酮耐药性超越II型拓扑异构酶修饰。
Antimicrob Agents Chemother. 2005 Dec;49(12):5051-7. doi: 10.1128/AAC.49.12.5051-5057.2005.
2
Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.不同氟喹诺酮类药物对体外筛选出的携带拓扑异构酶突变的炭疽芽孢杆菌突变株的活性。
Antimicrob Agents Chemother. 2004 Aug;48(8):3024-7. doi: 10.1128/AAC.48.8.3024-3027.2004.
3
Quinolone resistance due to reduced target enzyme expression.由于靶酶表达降低导致的喹诺酮耐药性。
J Bacteriol. 2003 Dec;185(23):6883-92. doi: 10.1128/JB.185.23.6883-6892.2003.
4
Activity of and resistance to moxifloxacin in Staphylococcus aureus.金黄色葡萄球菌对莫西沙星的活性及耐药性
Antimicrob Agents Chemother. 2003 Apr;47(4):1410-5. doi: 10.1128/AAC.47.4.1410-1415.2003.
5
Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureus.金黄色葡萄球菌中吉米沙星对拓扑异构酶的靶向作用及耐药性
Antimicrob Agents Chemother. 2003 Jan;47(1):274-82. doi: 10.1128/AAC.47.1.274-282.2003.
6
gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.gyrA和gyrB突变与艰难梭菌对环丙沙星和莫西沙星的交叉耐药性有关。
Antimicrob Agents Chemother. 2002 Nov;46(11):3418-21. doi: 10.1128/AAC.46.11.3418-3421.2002.
7
Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.金黄色葡萄球菌中加替沙星与AM-1121及环丙沙星相比的耐药机制和耐药频率
Antimicrob Agents Chemother. 2001 Oct;45(10):2755-64. doi: 10.1128/AAC.45.10.2755-2764.2001.
8
New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.对氟喹诺酮耐药的肺炎球菌体外突变体中parE基因的新突变。
Antimicrob Agents Chemother. 2001 Mar;45(3):952-5. doi: 10.1128/AAC.45.3.952-955.2001.
9
Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.金黄色葡萄球菌对普马沙星的耐药机制及频率：新突变提示新的药物-靶点相互作用
Antimicrob Agents Chemother. 2000 Dec;44(12):3344-50. doi: 10.1128/AAC.44.12.3344-3350.2000.
10
Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis.金黄色葡萄球菌中拓扑异构酶IV和DNA促旋酶的选择性靶向作用：喹诺酮类药物诱导的DNA合成抑制的不同模式
Antimicrob Agents Chemother. 2000 Aug;44(8):2160-5. doi: 10.1128/AAC.44.8.2160-2165.2000.
本文引用的文献
1
Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.金黄色葡萄球菌拓扑异构酶IV和DNA促旋酶的突变：对喹诺酮和香豆素活性的新型多效性影响。
Antimicrob Agents Chemother. 1998 Jan;42(1):121-8. doi: 10.1128/AAC.42.1.121.
2
Topoisomerase IV, not gyrase, decatenates products of site-specific recombination in Escherichia coli.在大肠杆菌中，拓扑异构酶IV而非回旋酶解开位点特异性重组的产物。
Genes Dev. 1997 Oct 1;11(19):2580-92. doi: 10.1101/gad.11.19.2580.
3
DNA gyrase, topoisomerase IV, and the 4-quinolones.DNA 回旋酶、拓扑异构酶IV与4-喹诺酮类药物。
Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. doi: 10.1128/mmbr.61.3.377-392.1997.
4
Crystal structure of the breakage-reunion domain of DNA gyrase.DNA 回旋酶断裂-重连结构域的晶体结构
Nature. 1997 Aug 28;388(6645):903-6. doi: 10.1038/42294.
5
Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.金黄色葡萄球菌和大肠杆菌II型DNA拓扑异构酶的差异行为
Antimicrob Agents Chemother. 1996 Dec;40(12):2714-20. doi: 10.1128/AAC.40.12.2714.
6
Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV.大肠杆菌喹诺酮耐药位点nfxD是编码拓扑异构酶IV一个亚基的parE基因的突变等位基因。
Antimicrob Agents Chemother. 1997 Jan;41(1):175-9. doi: 10.1128/AAC.41.1.175.
7
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.拓扑异构酶IV中的喹诺酮耐药性突变：与flqA位点的关系以及金黄色葡萄球菌中拓扑异构酶IV是氟喹诺酮类药物的主要靶点而DNA回旋酶是次要靶点的遗传学证据。
Antimicrob Agents Chemother. 1996 Aug;40(8):1881-8. doi: 10.1128/AAC.40.8.1881.
8
Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.负责金黄色葡萄球菌喹诺酮耐药性的DNA拓扑异构酶IV grlA基因的改变。
Antimicrob Agents Chemother. 1996 May;40(5):1157-63. doi: 10.1128/AAC.40.5.1157.
9
Structure and mechanism of DNA topoisomerase II.DNA拓扑异构酶II的结构与机制。
Nature. 1996 Jan 18;379(6562):225-32. doi: 10.1038/379225a0.
10
Topoisomerase IV is a target of quinolones in Escherichia coli.拓扑异构酶IV是喹诺酮类药物在大肠杆菌中的作用靶点。
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11801-5. doi: 10.1073/pnas.92.25.11801.
Zotero 插件